Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis

被引：0
|
作者：
Fu, S. [1 ]
Liu, J. [1 ]
Fu, P. [2 ]
Li, H. [3 ]
Yang, X. [3 ]
Xie, C. [1 ]
Zhang, J. [1 ]
机构：
[1] Shandong Univ, Shandong Canc Hosp & Inst, Jinan, Peoples R China
[2] Jinan Zhangqiu Dist Peoples Hosp, Jinan, Peoples R China
[3] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
EGFR mutant NSCLC; Brain Metastasis; Aumolertinib combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-03
引用
收藏
页码：S414 / S415
页数：2
相关论文
共 50 条
  • [31] A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
    Yang, James Chih-Hsin
    Cheng, Ying
    Murakami, Haruyasu
    Yang, Pan-Chyr
    He, Jianxing
    Nakagawa, Kazuhiko
    Kang, Jin Hyoung
    Kim, Joo-Hang
    Hozak, Rebecca R.
    Tuan Stevon Nguyen
    Zhang, Wan Li
    Enatsu, Sotaro
    Puri, Tarun
    Orlando, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 91 - 100
  • [32] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR Mutated Non-small Cell Lung Cancer with Brain Metastases
    Huang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S431 - S432
  • [33] First-line treatment of EGFR mutation adenosquamous carcinoma of the lung with aumolertinib: A multicenter, single-arm, prospective study (ARISE Study)
    Lin, Gen
    Huang, Long
    Chu, Qian
    Huang, Dingzhi
    Liu, Zhe
    Yu, Yongfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] RESTROSPECTIVE COMPARATIVE STUDY OF CARBOPLATIN/PEMETREXED/BEVACIZUMAB AND PEMETREXED/CARBOPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED NSCLC
    Magallanes, Manuel E.
    Cadena, Angelica C.
    Mendoza, Daniel
    Zincer, Fernando P.
    Bautista, Yolanda L.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S126 - S126
  • [35] Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A RealWorld Study
    Yan, N. N.
    Guo, S.
    Huang, S.
    Zhang, H.
    Li, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S622 - S622
  • [36] A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases
    Zhang, X.
    Zhang, M.
    Du, X.
    Zhang, G.
    Niu, Y.
    Wei, C.
    Guo, L.
    Shi, C.
    Wang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S660 - S660
  • [37] EGFR TKIS IN EGFR MUTATION-POSITIVE NSCLC WITH BRAIN METASTASIS
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [38] Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study
    Chen, L. K.
    Chen, J.
    Li, M. C.
    Yu, H.
    Zhang, B. S.
    Hou, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S48 - S49
  • [39] Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated with First-Line TKI
    Sharma, S.
    Lee, C.
    Miao, E.
    Seetharamu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S808 - S809
  • [40] Bevacizumab plus atezolizumab and chemotherapy in NSCLC harbouring EGFR mutation previously treated with EGFR tyrosine kinase inhibitor: The BACH-NET study
    Pasello, G.
    Lorenzi, M.
    Crivellaro, G.
    Capelletto, E.
    Buttice, S.
    Perrone, F.
    Tiseo, M.
    Scotti, V.
    Polo, V.
    Favaretto, A.
    Montrone, M.
    Berardi, R.
    Zustovich, F.
    Toschi, L.
    Bearz, A.
    Milella, M.
    Frega, S.
    Bonanno, L.
    Guarneri, V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S52 - S53
12345